newsfilter
← Latest News
GlobeNewswire·

Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

NDA supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls Remibetadex has received Orphan Drug, Fast Track and Rare